Custom-Made vaccine aims to stop breast cancer return
NCT ID NCT06435351
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This early-phase trial tests a personalized vaccine made from a patient's own immune cells and tumor proteins. The goal is to train the immune system to recognize and attack any remaining cancer cells after standard chemotherapy and surgery. Sixteen high-risk triple negative breast cancer patients will receive the vaccine to see if it is safe and triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen dendritic cell vaccine
What this could lead to
If successful, this could lead to a new treatment option that helps prevent breast cancer from coming back in high-risk patients.
What could go wrong
This is a very early, small trial with only 16 participants, so results may not apply to everyone. The vaccine may not trigger a strong immune response or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.